Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434923 | 0.79 | ROR1 (0.36) | ALDH1A1PTPN1ROR1NPY1RCYP19A1 | |
| SCHEMBL613626 | 0.78 | ROR1 (0.36) | ALDH1A1PTPN1ROR1NPY1RF2RL3 | |
| SCHEMBL6433053 | 0.76 | ROR1 (0.40) | PDE10APTPN1ROR1NPY1RCYP19A1 | |
| SCHEMBL6437802 | 0.75 | ALDH1A1 (0.36) | PDE10AALDH1A1POLBPTPN1ROR1 | |
| SCHEMBL6433066 | 0.74 | SCN9A (0.34) | PTPN1ROR1NPY1R | |
| SCHEMBL615752 | 0.74 | ROR1 (0.37) | ALDH1A1PTPN1ROR1CYP19A1 | |
| SCHEMBL615753 | 0.74 | ROR1 (0.37) | ALDH1A1PTPN1ROR1CYP19A1 | |
| SCHEMBL6439221 | 0.73 | ROR1 (0.36) | ALDH1A1ROR1CYP19A1 | |
| SCHEMBL6434408 | 0.72 | ROR1 (0.35) | ALDH1A1PTPN1ROR1NPY1RCYP19A1 | |
| SCHEMBL6438560 | 0.72 | ROR1 (0.41) | PDE10APTPN1ROR1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1165495-B1 | RESORCINOL DERIVATIVES | PFIZER (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| EP-1318974-A2 | RESORCINOL DERIVATIVES | Pfizer Products Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002024613-A2 | RESORCINOL DERIVATIVES | PFIZER PRODUCTS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1165495-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056702-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | PDE10A 2421/4885GRIN1 2588/4885GRIN2B 3657/4885 |
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | PDE10A 2443/4885GRIN1 2447/4885GRIN2B 3546/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | PDE10A 2421/4885GRIN1 2588/4885GRIN2B 3657/4885 |
| US-20020137961-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | PDE10A 2443/4885GRIN1 2447/4885GRIN2B 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.